- Home
- WPP vs RYTM Comparison
WPP vs RYTM Comparison
Compare WPP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- RYTM
- Stock Information
- Founded
- WPP 1985
- RYTM 2008
- Country
- WPP United Kingdom
- RYTM United States
- Employees
- WPP N/A
- RYTM N/A
- Industry
- WPP Advertising
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- WPP Consumer Discretionary
- RYTM Health Care
- Exchange
- WPP Nasdaq
- RYTM Nasdaq
- Market Cap
- WPP 5.9B
- RYTM 6.4B
- IPO Year
- WPP N/A
- RYTM 2017
- Fundamental
- Price
- WPP $26.82
- RYTM $95.68
- Analyst Decision
- WPP Sell
- RYTM Strong Buy
- Analyst Count
- WPP 1
- RYTM 13
- Target Price
- WPP N/A
- RYTM $101.92
- AVG Volume (30 Days)
- WPP 360.8K
- RYTM 569.8K
- Earning Date
- WPP 08-07-2025
- RYTM 11-04-2025
- Dividend Yield
- WPP 9.61%
- RYTM N/A
- EPS Growth
- WPP 86.47
- RYTM N/A
- EPS
- WPP 0.47
- RYTM N/A
- Revenue
- WPP $19,423,208,660.00
- RYTM $156,287,000.00
- Revenue This Year
- WPP N/A
- RYTM $44.69
- Revenue Next Year
- WPP N/A
- RYTM $63.53
- P/E Ratio
- WPP $11.12
- RYTM N/A
- Revenue Growth
- WPP N/A
- RYTM 53.55
- 52 Week Low
- WPP $24.28
- RYTM $45.91
- 52 Week High
- WPP $57.37
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- WPP 47.77
- RYTM 45.98
- Support Level
- WPP $26.70
- RYTM $97.47
- Resistance Level
- WPP $27.50
- RYTM $102.46
- Average True Range (ATR)
- WPP 0.42
- RYTM 3.22
- MACD
- WPP 0.19
- RYTM -1.46
- Stochastic Oscillator
- WPP 56.87
- RYTM 10.63
About WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.